Information Provided By:
Fly News Breaks for February 21, 2017
AMPH
Feb 21, 2017 | 09:52 EDT
Wells Fargo analyst David Maris said the fact that the FDA issued a Complete Response Letter, or CRL, to Amphastar on its nasal naloxone product was both "disappointing and surprising" given that the company currently markets the leading injectable generic naloxone. However, the stock's decline in pre-market trading "seems to more than reflect the nasal naloxone opportunity," added Maris, who keeps an Outperform rating on Amphastar shares, which are down 15% in early trading after the opening bell to $15.62.
News For AMPH From the Last 2 Days
There are no results for your query AMPH
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.